Efficiency and Transparency in Petitions Act
United States116th CongressS-660Senate
Updated: Mar 5, 2019
Summary
Efficiency and Transparency in Petitions Act This bill requires a petition regarding a pending generic drug or biological product application to be submitted to the Food and Drug Administration (FDA) within one year of when the petitioner discovers the issue that is the basis for the petition. The FDA may grant a waiver of the one-year deadline.
Bill texts
All available records shown.
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Senate
All available records shown.